Bellamy’s Australia Ltd shares hit an all-time high on broker upgrade

The Bellamy’s Australia Ltd (ASX: BAL) share price has rebounded from yesterday’s decline and stormed 9% higher to a record high of $16.30 on Friday.

The good news for shareholders is that one leading broker doesn’t expect the gains to stop there.

According to a note out of Goldman Sachs, the broker saw enough in the infant formula company’s half-year results release to upgrade its shares from neutral to a buy rating.

Furthermore, its analysts have increased their 12-month price target all the way to $18.00. This implies potential upside of over 10% from the record-high it made earlier today.

Why is Goldman Sachs so bullish?

This upgrade has largely been made on the back of its belief that Bellamy’s gross margin expansion opportunity is under appreciated by the market.

Goldman thinks that gross margins could lift largely due to a reduction in unit costs of ingredients and production as volumes rise and also through the renegotiation of a number of legacy supply agreements. The broker thinks these are likely to have unfavourable pricing terms currently.

Because of this the broker has increased its earnings estimates for FY 2018 through to FY 2020.

In FY 2018 earnings per share are now expected to come in at 40 cents, before rising to 62 cents in FY 2019, and then 79 cents in FY 2020. Previously Goldman had expected earnings per share of 39 cents, 55 cents, and 68 cents, respectively.

Should you invest?

I think Goldman makes some valid points in its report and investors should take note of its recommendation and consider snapping up shares today.

I feel confident that Bellamy’s is positioned perfectly to capitalise on the insatiable demand for ANZ infant formula and expect it to deliver on Goldman’s bullish forecasts.

Which means its shares are currently priced at approximately 26x estimated FY 2019 earnings. I don’t think this is overly expensive given its current growth profile, just as long as its CFDA approval comes in as expected in the middle of the year.

All in all, I think Bellamy’s may represent even better value for money that A2 Milk Company Ltd (ASX: A2M) and is certainly a better option to smaller rivals Bubs Australia Ltd (ASX: BUB) and Wattle Health Australia Ltd (ASX: WHA).

Here are three more growth shares that could be in line to beat the market this year like Bellamy's.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.